Zobrazeno 1 - 10
of 33
pro vyhledávání: '"Ozlem Tureci"'
Autor:
Alexander Muik, Jasmin Quandt, Bonny Gaby Lui, Maren Bacher, Sebastian Lutz, Maika Grünenthal, Aras Toker, Jessica Grosser, Orkun Ozhelvaci, Olga Blokhina, Svetlana Shpyro, Isabel Vogler, Nadine Salisch, Özlem Türeci, Ugur Sahin
Publikováno v:
Cell Reports, Vol 43, Iss 8, Pp 114567- (2024)
Summary: Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) exposure histories become increasingly complex through original and variant-adapted vaccines and infections with viral variants. Upon exposure to the highly altered Omicron spike g
Externí odkaz:
https://doaj.org/article/6d3ec055e6634edda15eec6aea826f60
Autor:
Timothy E. Albertson, Caitlin Hansen, Smiti Bihari, Juleen Gayed, Xia Xu, J. Abraham Simón-Campos, Michael E. Dever, Jose F. Cardona, Essack Mitha, Jeffrey B. Baker, Georgina Keep, Islamiat Oladipupo, Federico J. Mensa, Ye Feng, Hua Ma, Kenneth Koury, Susan Mather, Claudia Ana Ianos, Annaliesa S. Anderson, Özlem Türeci, Uǧur Şahin, William C. Gruber, Alejandra Gurtman, Charu Sabharwal, Nicholas Kitchin, the C4591031, C4591007 Clinical Trial Groups
Publikováno v:
Infectious Diseases and Therapy, Vol 13, Iss 4, Pp 699-714 (2024)
Abstract Introduction Rare myocarditis and pericarditis cases have occurred in coronavirus disease 2019 (COVID-19) messenger RNA (mRNA) vaccine recipients. Troponin levels, a potential marker of myocardial injury, were assessed in healthy participant
Externí odkaz:
https://doaj.org/article/90c062f7697b4812bbed4dc9541f00d7
Autor:
Frank van den Ouweland, Nicola Charpentier, Özlem Türeci, Ruben Rizzi, Federico J. Mensa, Claudia Lindemann, Shanti Pather
Publikováno v:
Human Vaccines & Immunotherapeutics, Vol 20, Iss 1 (2024)
ABSTRACTThe pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) led to urgent actions by innovators, vaccine developers, regulators, and other stakeholders to ensure public access to protective vaccines while maintaining r
Externí odkaz:
https://doaj.org/article/c254c20d203c4d8991baa392933b69e6
Autor:
Louise Murdoch, Karen Quan, James A. Baber, Agnes W. Y. Ho, Ying Zhang, Xia Xu, Claire Lu, David Cooper, Kenneth Koury, Stephen P. Lockhart, Annaliesa S. Anderson, Özlem Türeci, Uğur Şahin, Kena A. Swanson, William C. Gruber, Nicholas Kitchin, the C4591030 Clinical Trial Group
Publikováno v:
Infectious Diseases and Therapy, Vol 12, Iss 9, Pp 2241-2258 (2023)
Abstract Introduction Vaccination is a critical tool for preventing coronavirus disease 2019 (COVID-19) and influenza illnesses. Coadministration of the COVID-19 vaccine, BNT162b2, with seasonal inactivated influenza vaccine (SIIV) can provide substa
Externí odkaz:
https://doaj.org/article/c10e41db0b574d23af185c6952e55029
Autor:
Adrian Georg Simon, Su Ir Lyu, Mark Laible, Stefan Wöll, Özlem Türeci, Uğur Şahin, Hakan Alakus, Luca Fahrig, Thomas Zander, Reinhard Buettner, Christiane Josephine Bruns, Wolfgang Schroeder, Florian Gebauer, Alexander Quaas
Publikováno v:
Journal of Translational Medicine, Vol 21, Iss 1, Pp 1-16 (2023)
Abstract Background The prognosis of esophageal adenocarcinoma (EAC) and gastric adenocarcinoma (GAC) remains poor, and new therapeutic approaches are urgently needed. Claudin 6 (CLDN6) is an oncofetal antigen that is largely absent in healthy tissue
Externí odkaz:
https://doaj.org/article/955b99c2c4e6441e84f326d2f0b2a4bd
Autor:
Juleen Gayed, Vishva Bangad, Xia Xu, Federico Mensa, Mark Cutler, Özlem Türeci, Uǧur Şahin, Kayvon Modjarrad, Kena A. Swanson, Annaliesa S. Anderson, Alejandra Gurtman, Nicholas Kitchin
Publikováno v:
Vaccines, Vol 12, Iss 7, p 734 (2024)
We report neutralization titer data against contemporary SARS-CoV-2 sublineages from an ongoing, phase 2/3, open-label, clinical trial of a single dose (30 μg) of an Omicron XBB.1.5-adapted BNT162b2 monovalent mRNA vaccine. The trial included health
Externí odkaz:
https://doaj.org/article/4918551c78fb4b61aeeec58f4aba83f5
Autor:
Hayat Bähr-Mahmud, Ursula Ellinghaus, Christiane R. Stadler, Leyla Fischer, Claudia Lindemann, Anuhar Chaturvedi, Jan Diekmann, Stefan Wöll, Imke Biermann, Bernhard Hebich, Caroline Scharf, Manuela Siefke, Alexandra S. Roth, Martin Rao, Kerstin Brettschneider, Eva-Maria Ewen, Uğur Şahin, Özlem Türeci
Publikováno v:
OncoImmunology, Vol 12, Iss 1 (2023)
ABSTRACTIMAB362/Zolbetuximab, a first-in-class IgG1 antibody directed against the cancer-associated gastric-lineage marker CLDN18.2, has recently been reported to have met its primary endpoint in two phase 3 trials as a first-line treatment in combin
Externí odkaz:
https://doaj.org/article/9d221a17a4384e5ba41b5f63a1b80c51
Autor:
Alexander Muik, Bonny Gaby Lui, Jasmin Quandt, Huitian Diao, Yunguan Fu, Maren Bacher, Jessica Gordon, Aras Toker, Jessica Grosser, Orkun Ozhelvaci, Katharina Grikscheit, Sebastian Hoehl, Niko Kohmer, Yaniv Lustig, Gili Regev-Yochay, Sandra Ciesek, Karim Beguir, Asaf Poran, Isabel Vogler, Özlem Türeci, Ugur Sahin
Publikováno v:
Cell Reports, Vol 42, Iss 8, Pp 112888- (2023)
Summary: Evolution of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant has led to the emergence of sublineages with different patterns of neutralizing antibody evasion. We report that Omicron BA.4/BA.5 breakthrough inf
Externí odkaz:
https://doaj.org/article/9beefa8d290946d3b470f10ccdbe5236
Autor:
Shanti Pather, Shabir A. Madhi, Benjamin J. Cowling, Paul Moss, Jeremy P. Kamil, Sandra Ciesek, Alexander Muik, Özlem Türeci
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
Externí odkaz:
https://doaj.org/article/5fe8163a2ae34a369b314f0138ddd1f0
Autor:
Shanti Pather, Shabir A. Madhi, Benjamin J. Cowling, Paul Moss, Jeremy P. Kamil, Sandra Ciesek, Alexander Muik, Özlem Türeci
Publikováno v:
Frontiers in Immunology, Vol 14 (2023)
The highly transmissible Omicron (B.1.1.529) variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) was first detected in late 2021. Initial Omicron waves were primarily made up of sub-lineages BA.1 and/or BA.2, BA.4, and BA.5 subseq
Externí odkaz:
https://doaj.org/article/01e4f920498645d885ebb7c23c7d6232